ZA200508726B - Method of obtaining gallium-68 and use thereof and device for carrying out said method - Google Patents
Method of obtaining gallium-68 and use thereof and device for carrying out said method Download PDFInfo
- Publication number
- ZA200508726B ZA200508726B ZA200508726A ZA200508726A ZA200508726B ZA 200508726 B ZA200508726 B ZA 200508726B ZA 200508726 A ZA200508726 A ZA 200508726A ZA 200508726 A ZA200508726 A ZA 200508726A ZA 200508726 B ZA200508726 B ZA 200508726B
- Authority
- ZA
- South Africa
- Prior art keywords
- chelating agent
- generator
- anion exchanger
- column
- elute
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 239000002738 chelating agent Substances 0.000 claims description 58
- 150000001450 anions Chemical class 0.000 claims description 27
- 230000008685 targeting Effects 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 21
- 230000001588 bifunctional effect Effects 0.000 claims description 19
- 229910052733 gallium Inorganic materials 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 6
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 claims description 4
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 108010028921 Lipopeptides Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 239000012609 strong anion exchange resin Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000012636 positron electron tomography Methods 0.000 description 13
- 239000000700 radioactive tracer Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- RZHKDBRREKOZEW-AAXZNHDCSA-N 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl] Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 RZHKDBRREKOZEW-AAXZNHDCSA-N 0.000 description 5
- 108700038672 Edotreotide Proteins 0.000 description 5
- 238000000163 radioactive labelling Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 4
- KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 description 3
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 Fe** Chemical class 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- VXAUWWUXCIMFIM-UHFFFAOYSA-M aluminum;oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Al+3] VXAUWWUXCIMFIM-UHFFFAOYSA-M 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 101100465550 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRE2 gene Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011847 diagnostic investigation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002019 disulfides Chemical group 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D59/00—Separation of different isotopes of the same chemical element
- B01D59/28—Separation by chemical exchange
- B01D59/30—Separation by chemical exchange by ion exchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B3/00—Extraction of metal compounds from ores or concentrates by wet processes
- C22B3/20—Treatment or purification of solutions, e.g. obtained by leaching
- C22B3/42—Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B58/00—Obtaining gallium or indium
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B59/00—Obtaining rare earth metals
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
- G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for
- G21H5/02—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for as tracers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P10/00—Technologies related to metal processing
- Y02P10/20—Recycling
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Environmental & Geological Engineering (AREA)
- Geology (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Geochemistry & Mineralogy (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Catalysts (AREA)
- Led Devices (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308407.6A GB0308407D0 (en) | 2003-04-11 | 2003-04-11 | Method of obtaining 68 GA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200508726B true ZA200508726B (en) | 2007-07-25 |
Family
ID=9956633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200508726A ZA200508726B (en) | 2003-04-11 | 2005-10-27 | Method of obtaining gallium-68 and use thereof and device for carrying out said method |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070031329A1 (pt) |
| EP (1) | EP1610886B1 (pt) |
| JP (1) | JP4671956B2 (pt) |
| KR (1) | KR20050119205A (pt) |
| CN (1) | CN100381196C (pt) |
| AT (1) | ATE448863T1 (pt) |
| AU (1) | AU2004228745B2 (pt) |
| BR (1) | BRPI0409114A (pt) |
| CA (1) | CA2520176C (pt) |
| DE (1) | DE602004024181D1 (pt) |
| DK (1) | DK1610886T3 (pt) |
| ES (1) | ES2336447T3 (pt) |
| GB (1) | GB0308407D0 (pt) |
| IL (2) | IL170863A (pt) |
| MX (1) | MXPA05010855A (pt) |
| NO (1) | NO20054614L (pt) |
| RU (1) | RU2343965C2 (pt) |
| WO (1) | WO2004089517A1 (pt) |
| ZA (1) | ZA200508726B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057225B4 (de) * | 2004-11-26 | 2006-10-12 | Johannes-Gutenberg-Universität Mainz | Verfahren und Vorrichtung zur Isolierung eines chemisch und radiochemisch gereinigten 68Ga-Radionuklids und zum Markieren eines Markierungsvorläufers mit dem 68Ga-Radionuklid |
| US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| US7586102B2 (en) | 2006-08-14 | 2009-09-08 | Board Of Regents The University Of Texas System | Automated system for formulating radiopharmaceuticals |
| WO2008108311A1 (ja) * | 2007-03-02 | 2008-09-12 | Nagasaki University | Ｇｅ吸着剤 |
| RU2010120765A (ru) * | 2007-12-03 | 2012-01-10 | Джи-И Хелткер Лимитед (GB) | ОЧИСТКА ЭЛЮАТА ГЕНЕРАТОРА 68Ge/68Ga ОТ Fe(III), ПРЕДНАЗНАЧЕННАЯ ДЛЯ УЛУЧШЕНИЯ ИЗБИРАТЕЛЬНОЙ РАДИОАКТИВНОСТИ РАДИОФАРМАЦЕВТИЧЕСКИХ СРЕДСТВ НА ОСНОВЕ 68Ga |
| KR101051084B1 (ko) | 2009-09-14 | 2011-07-21 | 서울대학교산학협력단 | [１８ｆ]폴리프라이드의 개선된 제조방법 |
| GB0922492D0 (en) * | 2009-12-23 | 2010-02-03 | Hammersmith Imanet Ltd | Method for obtaining 68GA |
| CN102834119B (zh) * | 2010-04-09 | 2015-02-04 | 拜耳医疗保健公司 | 放射性药物浓度测量系统和方法 |
| GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| TWI397421B (zh) * | 2010-07-14 | 2013-06-01 | Inst Nuclear Energy Res Atomic Energy Council | 鎵－６８放射性同位素產生裝置及其方法 |
| CN101890297B (zh) * | 2010-07-16 | 2012-06-27 | 中国人民解放军第四军医大学 | 一种放射性核素镓-68的浓缩纯化方法 |
| RU2464043C1 (ru) * | 2011-09-26 | 2012-10-20 | Федеральное государственное бюджетное учреждение "Федеральный медицинский биофизический центр имени А.И. Бурназяна" | СПОСОБ ПОЛУЧЕНИЯ РАСТВОРОВ 68Ga ВЫСОКОЙ ЧИСТОТЫ |
| WO2013082699A1 (en) | 2011-12-08 | 2013-06-13 | Nordion (Canada) Inc. | Method of pre-treating an adsorbent for a chromatographic separation |
| RU2522892C1 (ru) * | 2013-01-09 | 2014-07-20 | Российская Федерация, от имени которой выступает Государственная корпорация по атомной энергии "Росатом" | Способ получения активной фармацевтической субстанции для синтеза препаратов галлия-68 |
| US9266084B2 (en) * | 2013-06-13 | 2016-02-23 | Institute Of Nuclear Energy Research | Automatic synthesizer apparatus for producing radiopharmaceutical tumor imaging agent Gallium-68-DOTATATE and method thereof |
| CN107405538B (zh) | 2015-01-30 | 2021-06-15 | 高级催化剂应用品国际有限公司 | 用于从来源于68Ge/68Ga发生器的洗脱物纯化Ga-68的工艺和用于所述工艺中的色谱柱 |
| CN106328237B (zh) * | 2015-06-29 | 2019-04-23 | 中国辐射防护研究院 | 一种放射性废离子交换树脂微波碳化、灰化工艺及专用装置 |
| WO2017144959A1 (pt) * | 2016-02-23 | 2017-08-31 | Serviço Nacional De Aprendizagem Industrial - Senai. | Equipamento para marcação de moléculas com gálio-68 |
| EP3503929B1 (en) * | 2016-08-26 | 2022-02-23 | Mayo Foundation for Medical Education and Research | Rapid isolation of cyclotron-produced gallium-68 |
| US11723992B2 (en) | 2018-08-03 | 2023-08-15 | Board Of Regents, The University Of Texas System | Method for extraction and purification of 68GA |
| WO2021070164A1 (en) * | 2019-10-12 | 2021-04-15 | Artms Products, Inc. | Systems and methods of isolation of gallium-68 |
| RU2714497C1 (ru) * | 2019-12-02 | 2020-02-18 | Общество с ограниченной ответственностью "НТЦ Амплитуда" | Применение ионообменных картриджей типа Chromafix HR-XC в Н+-форме и Chromafix 30-PS в НСО3-форме в устройстве для очистки и концентрирования элюата генератора 68Ge/68Ga |
| CN113144225A (zh) * | 2021-03-30 | 2021-07-23 | 广东回旋医药科技股份有限公司 | 一种高放射性核纯度的68Ga-GaCl3溶液的制备方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5213740B2 (pt) * | 1972-07-04 | 1977-04-16 | ||
| US4288424A (en) * | 1979-01-15 | 1981-09-08 | Massachusetts Institute Of Technology | Generator for ionic gallium-68 based on column chromatography |
| DE2932948C2 (de) * | 1979-08-14 | 1982-11-18 | Stiftung Deutsches Krebsforschungszentrum, 6900 Heidelberg | Verfahren zur Herstellung eines Ionenaustauschers und dessen Verwendung |
| US4330507A (en) * | 1980-06-11 | 1982-05-18 | New England Nuclear Corporation | Method and system for generating and collecting gallium-68 using alkaline eluant |
| DE4231622C2 (de) * | 1992-09-22 | 1996-09-05 | Bakelite Ag | Verfahren zur Herstellung von Metallneutralkomplexen mit hoher Koordinationszahl und deren Verwendung |
| JPH11130431A (ja) * | 1997-10-30 | 1999-05-18 | Hamamatsu Photonics Kk | 無水塩化ガリウム６８およびポルフィリン誘導体のガリウム６８錯体 |
| US6071490A (en) * | 1998-05-07 | 2000-06-06 | Immunomedics, Inc. | Position emission tomography using gallium-68 chelates |
| US7011816B2 (en) * | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
-
2003
- 2003-04-11 GB GBGB0308407.6A patent/GB0308407D0/en not_active Ceased
-
2004
- 2004-04-08 JP JP2006506105A patent/JP4671956B2/ja not_active Expired - Lifetime
- 2004-04-08 BR BRPI0409114-0A patent/BRPI0409114A/pt not_active IP Right Cessation
- 2004-04-08 ES ES04726535T patent/ES2336447T3/es not_active Expired - Lifetime
- 2004-04-08 DE DE602004024181T patent/DE602004024181D1/de not_active Expired - Lifetime
- 2004-04-08 DK DK04726535.0T patent/DK1610886T3/da active
- 2004-04-08 CN CNB2004800095966A patent/CN100381196C/zh not_active Expired - Lifetime
- 2004-04-08 EP EP04726535A patent/EP1610886B1/en not_active Expired - Lifetime
- 2004-04-08 RU RU2005130865/15A patent/RU2343965C2/ru not_active IP Right Cessation
- 2004-04-08 MX MXPA05010855A patent/MXPA05010855A/es active IP Right Grant
- 2004-04-08 KR KR1020057019261A patent/KR20050119205A/ko not_active Application Discontinuation
- 2004-04-08 US US10/552,206 patent/US20070031329A1/en not_active Abandoned
- 2004-04-08 AU AU2004228745A patent/AU2004228745B2/en not_active Ceased
- 2004-04-08 CA CA2520176A patent/CA2520176C/en not_active Expired - Fee Related
- 2004-04-08 WO PCT/GB2004/001548 patent/WO2004089517A1/en active Application Filing
- 2004-04-08 AT AT04726535T patent/ATE448863T1/de not_active IP Right Cessation
-
2005
- 2005-09-14 IL IL170863A patent/IL170863A/en not_active IP Right Cessation
- 2005-10-07 NO NO20054614A patent/NO20054614L/no not_active Application Discontinuation
- 2005-10-27 ZA ZA200508726A patent/ZA200508726B/en unknown
-
2009
- 2009-05-21 IL IL198894A patent/IL198894A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1780679A (zh) | 2006-05-31 |
| CA2520176C (en) | 2012-06-05 |
| AU2004228745A1 (en) | 2004-10-21 |
| JP4671956B2 (ja) | 2011-04-20 |
| DE602004024181D1 (de) | 2009-12-31 |
| MXPA05010855A (es) | 2005-12-14 |
| JP2006526764A (ja) | 2006-11-24 |
| IL198894A0 (en) | 2010-02-17 |
| AU2004228745B2 (en) | 2009-06-11 |
| DK1610886T3 (da) | 2010-03-29 |
| KR20050119205A (ko) | 2005-12-20 |
| CA2520176A1 (en) | 2004-10-21 |
| NO20054614L (no) | 2005-10-07 |
| IL170863A (en) | 2012-01-31 |
| WO2004089517A1 (en) | 2004-10-21 |
| RU2343965C2 (ru) | 2009-01-20 |
| EP1610886A1 (en) | 2006-01-04 |
| GB0308407D0 (en) | 2003-05-21 |
| US20070031329A1 (en) | 2007-02-08 |
| RU2005130865A (ru) | 2006-06-10 |
| CN100381196C (zh) | 2008-04-16 |
| ATE448863T1 (de) | 2009-12-15 |
| ES2336447T3 (es) | 2010-04-13 |
| EP1610886B1 (en) | 2009-11-18 |
| BRPI0409114A (pt) | 2006-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200508726B (en) | Method of obtaining gallium-68 and use thereof and device for carrying out said method | |
| ZA200508727B (en) | Microwave method for preparing radiolabelled gallium complexes | |
| McInnes et al. | Copper, gallium and zirconium positron emission tomography imaging agents: The importance of metal ion speciation | |
| Huclier-Markai et al. | Promising scandium radionuclides for nuclear medicine: a review on the production and chemistry up to in vivo proofs of concept | |
| KR100650506B1 (ko) | 방사성 의약품용 레늄-트리카보닐 착물 및 그 전구체의제조방법 | |
| US8663597B2 (en) | Method for obtaining 68Ga | |
| Daha et al. | Production of 177 Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical | |
| US20100256331A1 (en) | 68Ga-Labelling of a Free and Macromolecule Conjugated Macrocyclic Chelator at Ambient Temperature | |
| Banerjee et al. | ^ 1^ 7^ 7Lu-DOTMP,^ 1^ 5^ 3Sm-DOTMP,^ 1^ 7^ 5Yb-EDTMP and^ 1^ 8^ 6^/^ 1^ 8^ 8Re-CTMP: Novel Agents for Bone Pain Palliation and Their Comparison with^ 1^ 5^ 3Sm-EDTMP | |
| Fritzberg et al. | Metallic radionuclides for radioimmunotherapy | |
| Ulin et al. | Method for obtaining 68Ga | |
| Varvarigou et al. | Development of radioactively labelled cancer seeking biomolecules for targeted radiotherapy | |
| Alrowaily et al. | The significance of coordination chemistry in the development of anti-cancer peptide-based radiopharmaceuticals | |
| JOUHARI et al. | PRODUCTION OF177LU AND FORMULATION OF ETHYLENE DIAMINE TETRAMETHYLENE PHOSPHONATE (EDTMP) KITS AS A BONE-SEEKING RADIOPHARMACEUTICAL |